# Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

> **NCT06256055** · PHASE1 · UNKNOWN · sponsor: **UTC Therapeutics Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Malignant Mesothelioma
- Colorectal Cancer
- Bile Duct Cancer
- Rectal Cancer
- Ovary Cancer
- Pancreatic Cancer
- Breast Cancer Female

## Interventions

- **BIOLOGICAL:** UCMYM802 Injection

## Key facts

- **NCT ID:** NCT06256055
- **Lead sponsor:** UTC Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-05
- **Primary completion:** 2025-03
- **Final completion:** 2025-04
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06256055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06256055, "Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06256055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*